GII

Senior Market Sales® Acquires Seniors Advisory Services, Louisiana's Largest Senior Insurance Brokerage

Retrieved on: 
Wednesday, March 6, 2024

OMAHA, Neb., March 6, 2024 /PRNewswire/ -- Senior Market Sales® (SMS), one of the industry's premier insurance marketing organizations, is expanding its distribution in the southern United States with the acquisition of Seniors Advisory Services (SAS), Louisiana's largest senior insurance brokerage agency.

Key Points: 
  • Agency Plans to Leverage SMS Technology, Products and Expertise to Grow Regionally
    OMAHA, Neb., March 6, 2024 /PRNewswire/ -- Senior Market Sales ® (SMS), one of the industry's premier insurance marketing organizations, is expanding its distribution in the southern United States with the acquisition of Seniors Advisory Services (SAS), Louisiana's largest senior insurance brokerage agency.
  • With SMS' resources, Seniors Advisory Services can reach more seniors with more of their health and wealth needs.
  • "Seniors Advisory Services is a pillar in Louisiana in Medicare Advantage, with a solid reputation and strong relationships that will help SMS expand its reach in the South," said SMS President Jim Summers.
  • "This is an exciting opportunity to grow together and to create more synergies with all of our acquired partners ."

Self-Insured Employers Turn to ARC Fertility for Improved Gender Equality, Expanded Access to Fertility Care

Retrieved on: 
Tuesday, December 5, 2023

By helping reverse these troubling trends, employers can do their part to address social determinants of health and achieve health equity across the workplace.

Key Points: 
  • By helping reverse these troubling trends, employers can do their part to address social determinants of health and achieve health equity across the workplace.
  • “This correlation works both ways: as access to ART improves, we also see gains in women’s rights.
  • Per capita income, the maternal mortality ratio, and female parliamentary ratio were all key predictors of access to reproductive care.
  • Results were similar across different cultures, as ART utilization is associated with gender equality even after controlling for each country’s level of development.

Susan Mchabcheb Joins Goodwill Industries International as Chief Development Officer

Retrieved on: 
Friday, July 21, 2023

ROCKVILLE, Md., July 21, 2023 /PRNewswire/ -- Goodwill Industries International (GII), a leading nonprofit organization dedicated to providing individuals with education and employment opportunities, is pleased to announce the appointment of Susan Mchabcheb as its new Chief Development Officer.

Key Points: 
  • ROCKVILLE, Md., July 21, 2023 /PRNewswire/ -- Goodwill Industries International (GII), a leading nonprofit organization dedicated to providing individuals with education and employment opportunities, is pleased to announce the appointment of Susan Mchabcheb as its new Chief Development Officer.
  • Prior to that, she was Chief Development Officer at Easterseals Inc. and has worked with Easterseals affiliate organizations to build relationship-based fundraising expertise.
  • "Susan has a passion for our mission and the people we serve," said Steven C. Preston, President and CEO of Goodwill Industries International.
  • "The opportunity to serve as Chief Development Officer for Goodwill Industries International is incredible," said Mchabcheb.

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Retrieved on: 
Thursday, July 6, 2023

SOUTH SAN FRANCISCO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.

Key Points: 
  • Results from this Phase 2 dose-ranging study also demonstrated that the bivalent norovirus vaccine candidate was well tolerated, with a favorable safety profile that included no vaccine-related serious adverse events (SAEs) and no dose limiting toxicity.
  • “Topline data reported today further validate the potential of our norovirus vaccine candidate and, more broadly, our oral vaccine platform,” said Dr. James F. Cummings, Vaxart’s Chief Medical Officer.
  • “These data, additional forthcoming data from this study, and the data we expect from our norovirus challenge study will help inform our selection of dosage levels in a larger Phase 2b study and support an End-of-Phase 2 meeting with the U.S. Food and Drug Administration.
  • These data, along with upcoming topline data from the ongoing Phase 2 G1.1 challenge study, will inform dosage amounts for a bivalent norovirus Phase 2b study, the next step in progressing the vaccine candidate.

"STAND UP FOR SCIENCE" SWISS BIOTECH INNOVATION ON DISPLAY AT THE BIO 2023 INTERNATIONAL CONVENTION IN BOSTON JUNE 5-8, 2023

Retrieved on: 
Thursday, May 18, 2023

ZURICH, May 18, 2023 /PRNewswire/ -- Swiss life science innovation will be on display again at the BIO 2023 convention in Boston.

Key Points: 
  • ZURICH, May 18, 2023 /PRNewswire/ -- Swiss life science innovation will be on display again at the BIO 2023 convention in Boston.
  • Switzerland Global Enterprise and Presence Switzerland will present 47 leading Swiss biotech stars at the SWISS BIOTECH pavilion demonstrating why Switzerland was once again voted the most innovative economy in the world in 2022 by the Global Innovation Index (GII).
  • Switzerland remains one of the most attractive business locations for both startups and world-leading technology companies and offers an outstanding framework for procuring capital.
  • Along with their partners, the Swiss Biotech Association, Presence Switzerland, Innosuisse and swissnex, S-GE and their representatives in the US, the Swiss Business Hub USA bring the leading-edge innovation that Switzerland is consistently recognized for to BIO 2023.

Goodwill Industries International Revamps Website to Better Serve Job Seekers Online

Retrieved on: 
Monday, March 27, 2023

ROCKVILLE, Md., March 27, 2023 /PRNewswire/ -- Goodwill Industries International (GII) recently debuted its redesigned website to better serve online job seekers searching for new skills training and career opportunities. The revamped website has seen a 20% increase in year-over-year web traffic since it went live in mid-December, with a daily average of 500 job seekers from across the country connecting to their local Goodwill career centers. 

Key Points: 
  • ROCKVILLE, Md., March 27, 2023 /PRNewswire/ -- Goodwill Industries International (GII) recently debuted its redesigned website to better serve online job seekers searching for new skills training and career opportunities.
  • The impact of the resources available on Goodwill.org is optimized when job seekers also access local Goodwill career coach and navigator services.
  • Testimonials from Goodwill Industries International (GII) Web users:
    "What most stood out to me on Goodwill.org is how easy it is to navigate," said Paul Gonzales, Goodwill Southern California job seeker.
  • "Goodwill's website has really made a positive impact on my life," said Hannah Harbison, career advancer through Goodwill Southern California.

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

Retrieved on: 
Monday, December 5, 2022

These results follow the previously announced positive recommendation from an independent safety data monitoring committee based on this same cohort.

Key Points: 
  • These results follow the previously announced positive recommendation from an independent safety data monitoring committee based on this same cohort.
  • These titers corresponded to a Geometric Mean Fold Rise (GMFR) versus baseline of more than 18-fold for HIL-214.
  • HilleVax cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
  • Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Xi'an rises up global sci-tech cluster list

Retrieved on: 
Thursday, September 22, 2022

It is considered to be the barometer of innovation and creation of the global economy, as well as being an important reference for economic decision-making in various countries, which has attracted worldwide attention.

Key Points: 
  • It is considered to be the barometer of innovation and creation of the global economy, as well as being an important reference for economic decision-making in various countries, which has attracted worldwide attention.
  • Each year, the GII ranks the top-level innovative capacity of around 130 countries and economies around the world.
  • Xi'an has sufficient confidence and a solid foundation for the optimal development of its scientific and technological innovation.
  • The concept of key and core technology was proposed in Xi'an and the Global Key & Core Technology Innovation Conference has been held in the city for six sessions.

HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

Retrieved on: 
Wednesday, August 31, 2022

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported that an independent safety data monitoring committee (DMC) completed a prespecified review of safety data from the 203 subjects enrolled in the run-in portion of NEST-IN1 (Norovirus Efficacy and Safety Trial for INfants, or NOR-212), the company’s Phase 2b trial for HIL-214, its investigational virus-like particle (VLP) based vaccine candidate, for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants. Based on this review, the DMC recommended continuation of NEST-IN1 without modification and enrollment has subsequently resumed.   

Key Points: 
  • The positive DMC recommendation and continuation of enrollment for the remaining 2,800 subjects in our Phase 2b NEST-IN1 study is an important milestone for HIL-214 and HilleVax, said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax.
  • The clinical trial protocol includes a prespecified 200 subject run-in to assess safety and immunogenicity.
  • HilleVax cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
  • Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

NIA highlights four key magnets to attract foreign investors, pushing Thailand as a "Global Hub" for international startups and investors

Retrieved on: 
Monday, August 1, 2022

The NIA reveals four key magnets that will attract foreigners to invest or do business in Thailand, supported by their resources and collaboration from the government and private sector.

Key Points: 
  • The NIA reveals four key magnets that will attract foreigners to invest or do business in Thailand, supported by their resources and collaboration from the government and private sector.
  • These areas cater to Thai and international startups and facilitate them in terms of business and investment.
  • Foreigners who are interested in doing business in Thailand often face challenges such as opening accounts, registering their businesses, and other legal difficulties.
  • The four key magnets to attract foreigners to do business or invest in Thailand are, 1) Competitive business costs: Thailand is a livable country and business costs are not high.